Indole derivatives as interleukin-4 gene expression inhibitors
US7169925B2 · kind B2 · utility
6Cited by
4References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 23, 2003 |
| Grant date | Jan 30, 2007 |
| Priority date | — |
| Expiry date | Oct 2, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention discloses and claims a new class of indole derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. It has now been found that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.